Bristol Myers Squibb Stock Price To Earnings To Growth
BMYB34 Stock | BRL 355.25 12.45 3.63% |
Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol Myers' financial success or failures. It also enables traders to predict the movement of Bristol Stock. The fundamental analysis module provides a way to measure Bristol Myers' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myers stock.
Bristol |
Bristol Myers Squibb Company Price To Earnings To Growth Analysis
Bristol Myers' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Bristol Myers Price To Earnings To Growth | 2.41 X |
Most of Bristol Myers' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition |
Based on the latest financial disclosure, Bristol Myers Squibb has a Price To Earnings To Growth of 2.4078 times. This is 239.13% higher than that of the Healthcare sector and 111.21% higher than that of the Drug Manufacturers - Major industry. The price to earnings to growth for all Brazil stocks is 50.76% higher than that of the company.
Bristol Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in price to earnings to growth category among its peers.
Bristol Fundamentals
Return On Equity | 0.18 | |||
Return On Asset | 0.0613 | |||
Profit Margin | 0.14 % | |||
Operating Margin | 0.20 % | |||
Current Valuation | 1.04 T | |||
Shares Outstanding | 2.13 B | |||
Price To Earning | 50.79 X | |||
Price To Book | 5.00 X | |||
Price To Sales | 18.62 X | |||
Revenue | 46.16 B | |||
Gross Profit | 36.02 B | |||
EBITDA | 18.54 B | |||
Net Income | 6.33 B | |||
Cash And Equivalents | 29.36 B | |||
Cash Per Share | 17.95 X | |||
Total Debt | 39.6 B | |||
Debt To Equity | 159.70 % | |||
Current Ratio | 3.88 X | |||
Book Value Per Share | 15.38 X | |||
Cash Flow From Operations | 16.21 B | |||
Earnings Per Share | 15.61 X | |||
Price To Earnings To Growth | 2.41 X | |||
Number Of Employees | 41 | |||
Beta | 0.42 | |||
Market Capitalization | 812.44 B | |||
Total Asset | 109.31 B | |||
Z Score | 12.0 | |||
Annual Yield | 0.03 % | |||
Net Asset | 109.31 B | |||
Last Dividend Paid | 2.19 |
About Bristol Myers Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Bristol Stock
When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.